SCHEMBL24050797

SCHEMBL24050797

COc1ccc(C(=O)COc2ccc(CC3SC(O)NC3=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.57
MPC2 O95563 2/20 0.56
CYP2C8 P10632 2/20 0.56
CYP2C9 P11712 2/20 0.56
MAPT P10636 4/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
BLM P54132 1/20 0.42
PLA2G4B P0C869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21504803 0.89 PPARG (0.71) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL24943391 0.89 PPARG (0.68) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL21504834 0.86 PPARG (0.52) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL19217604 0.84 FFAR1 (0.45) PPARGMPC2CYP2C8CYP2C9RAB9A
SCHEMBL23836847 0.82 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL937521 0.82 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL24050788 0.81 PPARG (0.55) PPARGMPC2CYP2C8CYP2C9ALDH1A1
SCHEMBL25833061 0.81 PPARG (0.55) PPARGMPC2CYP2C8CYP2C9ALDH1A1
SCHEMBL21504808 0.79 PPARG (0.56) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL21504810 0.79 PPARG (0.56) PPARGMPC2CYP2C8CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210361629-A1 THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES CIRIUS THERAPEUTICS, INC. 2021-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361629-A1 THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES PPARD, FABP1, GOT2 PPARG 4/4885MPC2 194/4885CYP2C8 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.